Dominari (DOMH) Stock Price, News & Analysis

Company Overview

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Key Stats

• Today's Range: $3.00 to $3.28
• 50-Day Range: $2.75 to $3.92
• 52-Week Range: $2.68 to $8.40
• Volume: 280,107 shs
• Average Volume: 266,336 shs
• Market Capitalization: $70.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Dominari Stock Analysis - MarketRank™

Dominari scored higher than 6% of companies evaluated by MarketBeat, and ranked 846th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Dominari has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Dominari has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dominari is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dominari is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dominari has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.22% of the float of Dominari has been sold short.

Short Interest Ratio / Days to Cover

Dominari has a short interest ratio ("days to cover") of 1.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dominari has recently increased by 9.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dominari does not currently pay a dividend.

Dividend Growth

Dominari does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Dominari this week, compared to 1 article on an average week.

Search Interest

12 people have searched for DOMH on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

2 people have added Dominari to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dominari insiders have not sold or bought any company stock.

Percentage Held by Insiders

55.30% of the stock of Dominari is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.48% of the stock of Dominari is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Record date for 5/29 Dividend: 5/15/2026
• Ex-Dividend for 5/29 Dividend: 5/15/2026
• Dividend Payable: 5/29/2026
• Today: 6/08/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DOMH
• Previous Symbol: NASDAQ:DOMH
• CIK: 12239
• Web: N/A
• Phone: (112) 745-1374
• Fax: 703-992-9348
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.43 million
• Net Margins: -31.37%
• Pretax Margin: -16.67%
• Return on Equity: -206.20%
• Return on Assets: -155.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.41
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $123.10 million
• Price / Sales: 0.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.28 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 22,610,000
• Free Float: 10,108,000
• Market Cap: $70.09 million
• Optionable: Not Optionable
• Beta: 0.80